Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,054 | 1,162 | 22:32 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | CROSSJECT reports financial results for 2024 | 82 | GlobeNewswire (Europe) | Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer... ► Artikel lesen | |
25.03. | CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO adrenal insufficiency program | 72 | GlobeNewswire (Europe) | Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals,... ► Artikel lesen | |
18.03. | CROSSJECT achieves key ZEPIZURE manufacturing batch stability milestones | 1 | GlobeNewswire (USA) | ||
12.02. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | 96 | GlobeNewswire (Europe) | Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free... ► Artikel lesen | |
19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 98 | GlobeNewswire (Europe) | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
11.12.24 | Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M | 2 | GlobeNewswire (USA) | ||
10.12.24 | Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m | 1 | GlobeNewswire (USA) | ||
CROSSJECT Aktie jetzt für 0€ handeln | |||||
09.12.24 | Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement | 1 | GlobeNewswire (USA) | ||
13.11.24 | Crossject's ZENEO Auto-Injector's usability further demonstrated in extreme HAZMAT conditions | 1 | GlobeNewswire (USA) | ||
22.10.24 | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 124 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
23.09.24 | Crossject reports financial results and business highlights for the first six months of 2024 | 240 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
19.08.24 | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 247 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen | |
18.07.24 | Crossject achieves key ZEPIZURE manufacturing milestone | 171 | GlobeNewswire (Europe) | Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is... ► Artikel lesen | |
10.07.24 | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine | 189 | GlobeNewswire (Europe) | Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies... ► Artikel lesen | |
26.06.24 | Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study | 234 | GlobeNewswire (Europe) | Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine... ► Artikel lesen | |
12.06.24 | Crossject appoints Dan Chiche, MD as Chief Medical Officer North America | 241 | GlobeNewswire (Europe) | Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes... ► Artikel lesen | |
14.05.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2024 | 775 | Xetra Newsboard | Das Instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY wird ex Kapitalmassnahme gehandelt am 14.05.2024 The instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY is traded ex capital... ► Artikel lesen | |
25.04.24 | Crossject reports audited financial results for 2023 | 230 | GlobeNewswire (Europe) | Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free... ► Artikel lesen | |
08.04.24 | XFRA 74C: WIEDERAUFNAHME/RESUMPTION | 273 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
02.04.24 | Crossject advances in its U.S. Strategy and reports Financial Results for 2023 | 316 | GlobeNewswire (Europe) | Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 39,480 | +0,28 % | DAX höher: Commerzbank, Porsche, Renk, BASF, Bayer, Airbus, Fresenius, Siemens Energy im Fokus | Der DAX hat am Dienstag nach einem starken ifo-Geschäftsklimaindex ordentlich Gas gegeben. Er ging letztendlich mit einem Plus von 1,1 Prozent auf 23.109,79 Zählern aus dem Handel. Und auch am Mittwoch... ► Artikel lesen | |
INTUITIVE SURGICAL | 460,10 | +0,46 % | UNGLAUBLICHE Sondermeldung bei Intuitive Surgical Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
SERNOVA BIOTHERAPEUTICS | 0,110 | +11,81 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
FAMICORD | 3,880 | -2,02 % | Vita 34 firmiert um: Neuer Name FamiCord AG | Die Vita 34 AG firmiert ab sofort unter dem Namen FamiCord AG. Der neue Name basiert auf der bekanntesten Konzernmarke und soll die Expansion des Leipziger Unternehmens in weitere Geschäftsfelder unterstützen.... ► Artikel lesen | |
GERATHERM MEDICAL | 3,220 | -5,29 % | Geratherm Medical Aktie: Ruhige Zeiten angekündigt? | Das Medizintechnikunternehmen passt Produktionskapazitäten für klinische Thermometer bei fortgesetzter Marktschwäche an, während die Aktie trotz Volatilität zuletzt zulegte. Die Geratherm Medical AG... ► Artikel lesen | |
ALIGN TECHNOLOGY | 148,60 | +1,19 % | Align Technology, Inc.: Align Technology Announces Invisalign System With Mandibular Advancement Featuring Occlusal Blocks for Class II Skeletal and Dental Correction | Offers an Innovative Treatment Option for Class II Skeletal Malocclusion in Kids and Teenage Patients While Simultaneously Straightening their Teeth
Align Technology, Inc. (Nasdaq: ALGN), a leading... ► Artikel lesen | |
NUGEN MEDICAL DEVICES | 0,031 | +13,87 % | Unglaubliche News! Der Super-CEO der alle Türen öffnen kann! | ||
PLUS THERAPEUTICS | 1,010 | +6,30 % | PLUS THERAPEUTICS, INC. - 10-K, Annual Report | ||
CARDINAL HEALTH | 126,95 | -0,43 % | Dividendenbekanntmachungen (01.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABB LTD CH0012221716 0,9892 USD 0,9143 EUR ABB LTD ADR US0003752047 0,9892 USD 0,9143 EUR AGILENT TECHNOLOGIES INC US00846U1016 0... ► Artikel lesen | |
RESMED | 205,70 | -0,63 % | Aktienmarkt: Kurs der ResMed-Aktie im Plus (207,3681 €) | Im Plus liegt derzeit der Anteilsschein von ResMed . Der jüngste Kurs betrug 224,14 US-Dollar. Heute hat sich im US-amerikanischen Wertpapierhandel die ResMed-Aktie zwischenzeitlich um 1,02 Prozent... ► Artikel lesen | |
DAVITA | 141,00 | -0,35 % | DaVita-Aktie: Kurs legt zu (141,3232 €) | Im US-amerikanischen Wertpapierhandel liegt die DaVita-Aktie zur Stunde im Plus. Das Wertpapier notiert aktuell bei 152,54 US-Dollar. Heute hat sich an der US-amerikanischen Börse das Wertpapier von... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,613 | -3,46 % | Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst | ||
MEDICLIN | 2,980 | 0,00 % | EQS-News: MEDICLIN AG: MEDICLIN beendet erfolgreiches Geschäftsjahr 2024 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Jahresbericht/Sonstiges
MEDICLIN beendet erfolgreiches Geschäftsjahr 2024
28.03.2025 / 10:24 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
UNIDOC HEALTH | 0,238 | +6,25 % | UniDoc schließt den Erwerb der Software AGNES Connect von AMD Telemedicine ab | VANCOUVER, British Columbia, 28. März 2025 / IRW-Press / UniDoc Health Corp. (CSE: UDOC) (FWB: L7T) (OTCQB: UDOCF) ("UniDoc" oder das "Unternehmen") gibt unter
Bezugnahme auf seine Pressemeldung... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Signs Sourcing Partnership With Windtree, Expects To Reduce Production Cost Of Phexxi By 60% |